The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Hypercholesterolemia; Management of Korean Patients in New Millennium

고콜레스테롤혈증; 새천년 한국에서는 어떤 환자를 어떻게 치료할 것인가?

Kim, Chee-Jeong;Lee, Kwang-Je
김치정;이광제

  • Published : 20070600
⟨ Previous Next ⟩

Abstract

Cardioprotective effect and the safety of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) has been established in many large-scaled randomized controlled trials encompassing both primary and secondary prevention. Therefore, the market of statins is growing rapidly. In new millennium, several studies have shown the benefit from further reducing already low concentration of low density lipoprotein-cholesterol in high-risk patients. However, these clinical trials have applied selection criteria to protect the internal validity at the expense of reducing the applicability of the trial's findings to the wider population of patients seen in routine clinical practice. Treatment guideline for Korean hypercholesterolemic patients followed that of American. However, the death rate by coronary artery diseases is much lower in Korean population than in American population. The efficacy of statins in preventing cardiovascular diseases and the pitfalls in recent randomized controlled trails will be reviewed and the personal opinion for the management of Korean hypercholesterolemic patients will be suggested.

Keywords

References

  1. Keys A, Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjevic BD, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor HL. Epiderniological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand suppl 480:1-392, 1967
  2. Law MR, Wald NJ, Thompson SG. Ey how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? EMJ 308:367-372, 1994
  3. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data Circulation 91:2274-2282, 1995 https://doi.org/10.1161/01.CIR.91.8.2274
  4. Davey Smith G, Song F, Sheldon T A. Cholesterol lowering and mortality: the importance of considering initial level of risk EMJ 306:1367-1373, 1993
  5. Cucherat M, Boissel J-P. Meta-analysis of results from clinical trials on prevention of coronary heart disease by lipid-lowering interventions. Clin Trials Meta-Anal 28:109-129, 1993
  6. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial inaraion. N Engl J Med 323:1112-1119, 1990 https://doi.org/10.1056/NEJM199010183231606
  7. Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol concentration and mortality: a quantitative review of primary prevention trials. EMJ 301:309-14, 1990
  8. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? EMJ 304:431-434,1992
  9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Effimcy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005 https://doi.org/10.1016/S0140-6736(05)67394-1
  10. 고지혈증 치료지침 제정위원회. 고지혈증 치료지침. 2nd ed. p. 79, 서울, 도서출판 한의학,2003
  11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark L T, Hunninghake DB, Pasternak RC, Smith SC jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004 https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  12. De Backer G, Ambrosioni E, Borch- Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. Third joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24:1601-1610,2003 https://doi.org/10.1016/S0195-668X(03)00347-6
  13. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 252:933-936, 1986
  14. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 257:2176-2180, 1987 https://doi.org/10.1001/jama.257.16.2176
  15. 4S group. Randornised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383-1389, 1994
  16. ShepherdJ, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995 https://doi.org/10.1056/NEJM199511163332001
  17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wamica rw, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial injarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001-1009, 1996 https://doi.org/10.1056/NEJM199610033351401
  18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998 https://doi.org/10.1001/jama.279.20.1615
  19. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357,1998 https://doi.org/10.1056/NEJM199811053391902
  20. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002 https://doi.org/10.1016/S0140-6736(02)09327-3
  21. Shepherd J, Blauw GJ, Murphy ME, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema lW, Kamper AM, Macfarlane PW, Meinders AE, Nome J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Prospective Study of Pravastatin in the Elderly at Risk. Lancet 360:1623-1630, 2002 https://doi.org/10.1016/S0140-6736(02)11600-X
  22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensiue and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hyper: cholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensioe and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007, 2002 https://doi.org/10.1001/jama.288.23.2998
  23. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan-average cholesterol concentrations, in the AngloSmndinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003 https://doi.org/10.1016/S0140-6736(03)12948-0
  24. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005 https://doi.org/10.1056/NEJMoa050461
  25. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stem T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. FJfects cf atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711-1718, 2001 https://doi.org/10.1001/jama.285.13.1711
  26. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307-1316, 2004 https://doi.org/10.1001/jama.292.11.1307
  27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504, 2004 https://doi.org/10.1056/NEJMoa040583
  28. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial irfarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445, 2005 https://doi.org/10.1001/jama.294.19.2437
  29. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559, 2006 https://doi.org/10.1056/NEJMoa061894
  30. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071-1080, 2004 https://doi.org/10.1001/jama.291.9.1071
  31. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004 https://doi.org/10.1016/S0140-6736(04)16895-5
  32. National Cholesterol Education Program. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148:36-69, 1988 https://doi.org/10.1001/archinte.148.1.36
  33. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89:1333-1445, 1994 https://doi.org/10.1161/01.CIR.89.3.1333
  34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel lII). JAMA 285:2486-2497, 2001 https://doi.org/10.1001/jama.285.19.2486
  35. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15:1300-1331, 1994 https://doi.org/10.1093/oxfordjournals.eurheartj.a060388
  36. Wood D, De Backer G, Faergeman 0, Graham I, Mancia G, Pyorala K Prevention of coronary heart disease in clinical practice: recommendations of the Second joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140:199-270, 1998 https://doi.org/10.1016/S0021-9150(98)90209-X
  37. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial irfarction. N Engl J Med 339:229-234,1998. https://doi.org/10.1056/NEJM199807233390404
  38. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, Ratner RE, Resnick HE, Devereux RB. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29:391-397, 2006 https://doi.org/10.2337/diacare.29.02.06.dc05-1299
  39. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105:1424-1428, 2002 https://doi.org/10.1161/01.CIR.0000012918.84068.43
  40. Buse jB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky j, Porte D, Redberg R, Stitzel KF, Stone NJ: American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115:114-126, 2007
  41. Dale KM, Coleman cr, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 295:74-80, 2006 https://doi.org/10.1001/jama.295.1.74
  42. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 176:649-654, 2007 https://doi.org/10.1503/cmaj.060803
  43. 통계청 2004년 사망원인통계연보(인구동태신고에 의한 집계). 서울. 통계청,2006
  44. Wayne Rosamond, Katherine Flegal, Gary Friday, Karen Furie, Alan Go, Kurt Greenlund, Nancy Haase, Michael Ho, Virginia Howard, Bret Kissela, Steven Kittner, Donald Lloyd-jones, Mary Mcljermott, james Meigs, Claudia Moy, Graham Nichol, Christopher J. 0' 'Donnell, Veronique Roger, john Rumsfeld, Paul Sorlie, julia Steinberger, Thomas Thorn, Sylvia Wasserthiel-Smoller, Yuling Hong and for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2oo7 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115;e69-e171, 2007 https://doi.org/10.1161/CIRCULATIONAHA.106.179918